536 reports of this reaction
1.7% of all BENRALIZUMAB reports
#12 most reported adverse reaction
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is the #12 most commonly reported adverse reaction for BENRALIZUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 536 FDA adverse event reports linking BENRALIZUMAB to INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. This represents approximately 1.7% of all 31,657 adverse event reports for this drug.
Patients taking BENRALIZUMAB who experience inappropriate schedule of product administration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is a less commonly reported adverse event for BENRALIZUMAB, but still significant enough to appear in the safety profile.
In addition to inappropriate schedule of product administration, the following adverse reactions have been reported for BENRALIZUMAB:
The following drugs have also been linked to inappropriate schedule of product administration in FDA adverse event reports:
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION has been reported as an adverse event in 536 FDA reports for BENRALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION accounts for approximately 1.7% of all adverse event reports for BENRALIZUMAB, making it a notable side effect.
If you experience inappropriate schedule of product administration while taking BENRALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.